Nov 11, 2017
MediSieve Wins CMS Healthcare Startup of the Year Award 2017
MediSieve have recently been announced winners of the CMS Healthcare Startup of the Year Award 2017 in the Beanstalks competition.
This news was announced at the GIANT Health Event, held at the Old Truman Brewery in London from 8-10 November. The prestigious award, now in its second year, was given to the startup medical company for their advances in magnetic blood filtration.
The Beanstalk Awards are a competition for startup companies with ideas, prototypes or advancements in the medical sector. The awards aim to celebrate, encourage and reward innovation within the medical sector, where entrepreneurs are making great strides towards actionable advances in technology in order to tackle some of our biggest diseases and conditions we are facing in today's world. Following their nomination for the TCT Magazine awards 2017 in the Healthcare Application category, the win comes as a shining example of the life-saving work MediSieve are continuing to be a part of and has instilled great confidence and pride into the heart of the company. The award for CMS Healthcare Startup of the Year as part of the Beanstalks competition will allow MediSieve to expand their business in new and exciting ways. As a reward for winning this prestigious prize, the company is entitled to a package of legal services which are worth anything up to the value of £8,000, as kindly provided by CMS. This will be tailored to the company's needs, and will allow them to develop in any legal area they choose, including everything from the development of new technology and patents, through to commercial contracts and share schemes.
MediSieve are excited about what this will mean for their future, and for their development as a company who are passionate about bringing brilliant new ideas into the healthcare industry. George Frodsham, founder and CEO MediSieve said: "It's an amazing achievement and we're all happy to have won the Beanstalks Competition Healthcare Startup of the Year award. Everyone has worked incredibly hard on our magnetic blood filtration device, and it's great to see all that work and the future applications being recognised. We're still working on ways to improve the device, to be able to broaden its applications and help to tackle some of the challenges that affect us all". The MediSieve device, an innovative medical blood-filtration device that magnetically filters particles from the bloodstream, is still undergoing extensive testing and research to be able to target the causes of specific diseases, such as sepsis and leukaemia, and is hoped to be able to improve treatments for cases of malaria.
Amir Amraie from GIANT Health Events said "our vision is to improve the health and well-being of people around the world, by promoting healthcare innovation and supporting health-tech entrepreneurs. And I believe with all and every one of you we were able to achieve this. This year we had over 100 health entrepreneurs from 18 countries applying and you are doing great work with MediSieve Limited." All of those who worked tirelessly on MediSieve's product and on ensuring it becomes an established product within the healthcare industry are incredibly proud of their achievement. To find out more about the Beanstalks Awards, visit http://beanstalks.gianthealthevent.com/
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: